These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 25951927

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J.
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A, Hatton GB, Merchant HA, Basit AW.
    Int J Pharm; 2015 Apr 30; 484(1-2):103-8. PubMed ID: 25721685
    [Abstract] [Full Text] [Related]

  • 5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA.
    Dan Med Bull; 2000 Feb 30; 47(1):20-41. PubMed ID: 10709142
    [Abstract] [Full Text] [Related]

  • 6. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
    Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R.
    Aliment Pharmacol Ther; 2019 May 30; 49(10):1301-1313. PubMed ID: 30895635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.
    Yu A, Baker JR, Fioritto AF, Wang Y, Luo R, Li S, Wen B, Bly M, Tsume Y, Koenigsknecht MJ, Zhang X, Lionberger R, Amidon GL, Hasler WL, Sun D.
    Mol Pharm; 2017 Feb 06; 14(2):345-358. PubMed ID: 28009518
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
    Thorpe MP, Ehrenpreis ED, Putt KS, Hannon B.
    Aliment Pharmacol Ther; 2009 Jun 01; 29(11):1193-201. PubMed ID: 19222409
    [Abstract] [Full Text] [Related]

  • 14. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
    Stobaugh DJ, Deepak P, Thorpe M, Hannon B, Ehrenpreis ED.
    Inflamm Bowel Dis; 2013 Feb 01; 19(2):301-8. PubMed ID: 22644716
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ.
    J Clin Gastroenterol; 2008 Apr 01; 42(4):338-44. PubMed ID: 18277908
    [Abstract] [Full Text] [Related]

  • 17. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May 18; 51(1312):38-9. PubMed ID: 19448588
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
    Kadiyala I, Jacobs D.
    Recent Pat Drug Deliv Formul; 2014 Apr 18; 8(1):3-11. PubMed ID: 24111938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.